Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May 30:77:100057.
doi: 10.1016/j.clinsp.2022.100057. eCollection 2022.

SARS-CoV-2 vaccines: Potential refinements through induction of mucosal and trained immunity

Amanda Izeli Portilho  1 , Gabrielle Gimenes Lima  1 , Elizabeth De Gaspari  2
Affiliations
Editorial

SARS-CoV-2 vaccines: Potential refinements through induction of mucosal and trained immunity

Amanda Izeli Portilho et al. Clinics (Sao Paulo). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declare no conflicts of interest.

References

    1. Sterlin D., Mathian A., Miyara M., et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;20(577):eabd2223. - PMC - PubMed
    1. Sepahi A., Salinas I. The evolution of nasal immune systems in vertebrates. Mol Immunol. 2016;69:131–138. - PMC - PubMed
    1. Mutsch M., Zhou W., Rhodes P., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's Palsy in Switzerland. N Engl J Med. 2004;350(9):896–903. - PubMed
    1. Kiyono H., Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol. 2004;4(9):699–710. - PMC - PubMed
    1. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–527. - PubMed

Publication types

Substances